Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Autoimmune Liver Disease
In what clinical scenario do you initiate the use of ileal bile acid transport (IBAT) inhibitors in the management of cholestatic liver disease?
Related Questions
How do you prefer to manage IgG-4 related hepato-biliary disease, especially if there are similarities in imaging findings to other immune mediated liver diseases?
In a serologic evaluation for immune-mediated liver disease, what further workup do you pursue when low immunoglobulins are identified?
What patient factors guide your selection of maintenance therapies for a patient with autoimmune hepatitis?
How will the recent withdrawal of Ocaliva for the treatment of PBC impact your therapeutic and management plan for these patients?
In what clinical scenario would you consider the use of budesonide over prednisone as part of the pharmacologic management of autoimmune hepatitis?
What is your strategy in the management of patients with autoimmune hepatitis who failed azathioprine therapy and what parameters do you monitor with what frequency?
How do you manage liver enzyme elevations in patients with PBC after starting elanifibranor?
What is your approach to treatment of immune-mediated overlap syndromes, such as AIH-PBC?
What is your strategy to manage pruritus in patients with cholestatic liver disease?
What is your approach to induction therapy and maintenance therapy for patients with autoimmune hepatitis?
